[A randomized, double-blind, placebo-controlled study of the efficacy and safety of ampasse in the treatment of chronic cerebral ischemia]. / Randomizirovannoe dvoinoe slepoe platsebo-kontroliruemoe issledovanie éffektivnosti i bezopasnosti preparata ampasse v terapii khronicheskoi ishemii mozga.

AIM: To study the efficacy and safety of ampasse in the treatment of chronic cerebral ischemia. MATERIAL AND METHODS: A randomized, double-blind, placebo-controlled study of the efficacy and safety of the 5-hydroxy-3-carboxypyridine-L-glutamine acid monocalcium salt (ampasse) was performed in 80 patients, aged from 50 to 75 years, with chronic cerebrovascular accident due to arterial hypertension and/or atherosclerosis of the main arteries of the head. The drug was used in daily doses of 5, 10, or 25 mg intravenously once a day for 15 days. Sodium chloride 0.9% was used as a placebo. RESULTS AND CONCLUSION: It has been established that ampasse improves the state of patients with chronic cerebral ischemia in relation to depression, sleep quality and cognitive functions.

[Endothelial dysfunction in ischemic strokes in diabetes mellitus].

The progression of an ischemic stroke concerns the activation of endothelial cells especially in patients with diabetes mellitus type 2. The aim of our study was to evaluate the endothelial dysfunction in patients with acute ischemic stroke with diabetes mellitus type 2. We measured the plasma activities of von Willebrand factor (vWf) as endothelial markers. The plasma vWf activities were significantly elevated in the index group compared to patients with ischemic stroke and arterial hypertension and controls. The correlation of the neurologic deficit severity to day 21 with the activity of endothelial dysfunction was revealed as well.

[Tanakan (EGb 761) in the therapy of mild cognitive impairment].

Mild Cognitive Impairment (MCI) means cognitive deterioration not yet causing disability or dementia. Aged patients with MCI constitute a group of high risk for Alzheimer disease and other types of dementia. Currently, there is no generally adopted approach to MCI management but medications with neuroprotective properties are presumed to be the most perspective. Presented are the results of a multicentral open-label clinical trial of vascular and neuroprotective drug tanakan (EGb 761). The study has shown the decrease of cognitive impairment, which was both clinically and statistically significant, in patients at early stages of vascular and neurodegenerative pathological process. Probable efficacy of long-term tanakan treatment in prevention of dementia is discussed.